Dr. Hope Rugo and advocate Jonise Louis discuss new ADCs, biomarker testing, and patient-centered dosing for metastatic ...

Triple-negative breast cancer is called “triple-negative” because the tumor lacks all three of these receptors. That absence is exactly what makes it more challenging to treat: These targeted forms of ...

Triple-negative breast cancer (TNBC) has long been one of the most difficult forms of breast cancer to treat. Unlike other breast cancer subtypes, TNBC lacks estrogen, progesterone, and HER2 receptors ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC), Datroway (datopotamab deruxtecan), has become the first drug to outperform chemotherapy in immunotherapy-ineligible metastatic ...

Read more about the newly discovered molecule, SU212, that impedes the growth of triple-negative breast cancer.

Triple negative breast cancer (TNBC) represents approximately 10-15% of all breast cancer diagnoses but accounts for a disproportionately high percentage of breast cancer deaths. What sets this ...

High levels of immune infiltrates are strongly prognostic for favorable outcomes independently of nodal status in triple-negative breast cancer (TNBC). Tumor-Infiltrating Lymphocytes (TILs) High ...

Texas A&M University study suggests that anthocyanins, found in dark sweet cherries, could play a role in slowing the ...

Add Yahoo as a preferred source to see more of our stories on Google. Eligible patients had received between one and four previous lines of chemotherapy. Credit: Thomas Andreas via Shutterstock.

Add Yahoo as a preferred source to see more of our stories on Google. AstraZeneca and Daiichi Sankyo's ADC AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC), Datroway (datopotamab ...